Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

 

B.Significant changes

 

A discussion of the significant changes in our business can be found under “Item 4. Information on the Company–A. History and development of the Company” and “Item 4. Information on the Company–B. Business Overview.”

 

ITEM 9. THE OFFER AND LISTING

 

A.Offering and listing details

 

See “–C. Markets” below.

 

B.Plan of distribution

 

Not applicable.

 

C.Selling shareholders

 

Not applicable.

 

D.Dilution

 

Not applicable.

 

E.Expenses of the issue

 

Not applicable.

 

ITEM 10. ADDITIONAL INFORMATION

 

A.Share capital

 

Not applicable.

 

B.Memorandum and articles of association

 

On March 26, 2018, we adopted updated Articles of Association reflecting the increase of the Company's issued share capital following various exercises of options and the corresponding adjustment of the conditional share capital increase for employee benefit plans. On July 19 and 30, 2018, we adopted two subsequent versions of our Articles of Association, in each case to reflect the increase of the Company’s issued share capital following the three offerings carried out in July 2018. The Articles of Association dated July 30, 2018 are filed as Exhibit 3.1 hereto.

 

We incorporate by reference into this annual report on Form 20-F the description of our Articles of Association contained in our Registration Statement on Form F-1 (File No. 333-211714) filed with the SEC on September 23, 2016, Form F-3 (File No. 333-224694) filed with the SEC on May 4, 2018 and Form F-3 (File No. 333-227016) filed with the SEC on August 24, 2018. Such description, together with the immediately preceding paragraph, sets forth a summary of certain provisions of our Articles of Association as currently in effect.

 

C.Material contracts

 

Except as otherwise disclosed in this Annual Report on Form 20-F (including the Exhibits), we are not currently, and have not been in the last two years, party to any material contract, other than contracts entered into in the ordinary course of business.

 

 128


© AC Immune 2015